See more : Pental Limited (PTL.AX) Income Statement Analysis – Financial Results
Complete financial analysis of Pressure BioSciences, Inc. (PBIO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Pressure BioSciences, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Puxin Limited (NEW) Income Statement Analysis – Financial Results
- Solid State System Co., Ltd. (3259.TWO) Income Statement Analysis – Financial Results
- Newcapec Electronics Co., Ltd. (300248.SZ) Income Statement Analysis – Financial Results
- Quadient S.A. (NPACF) Income Statement Analysis – Financial Results
- Ecolutions GmbH&Co KGaA (MLECO.PA) Income Statement Analysis – Financial Results
Pressure BioSciences, Inc. (PBIO)
About Pressure BioSciences, Inc.
Pressure BioSciences, Inc. develops and sells pressure-based platform solutions in the North America, Europe, and Asia. The company's pressure cycling technology (PCT) technology uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control the actions of molecules in biological samples, including cells and tissues from human, animal, plant, and microbial sources. It offers Barocycler instrumentations comprising Barocycler 2320EXT, Barocycler HUB880, Barocycler HUB440, and The Shredder SG3. The company also distributes cell disruption equipment, parts, and consumables. In addition, it offers Barocycler consumable products, such as PCT MicroTubes, PCT MicroCaps, PCT-Micro Pestle, and pressure used to lyse samples for extraction tubes, as well as application specific kits, including consumable products and reagents. The company serves researchers at academic laboratories, government agencies, biotechnology companies, pharmaceutical firms, and other life science institutions. It has collaborations with RedShiftBio Inc.; Inova Schar Cancer Center; NYU; Leica Microsystems, GmbH; Steinbeis Centre for biopolymer analysis and biological mass spectrometry; The Ohio State University; University of Delaware; and Cedars Sinai Medical Center. The company was formerly known as Boston Biomedica, Inc. Pressure BioSciences, Inc. was incorporated in 1978 and is based in South Easton, Massachusetts. As of August 2, 2022, Pressure BioSciences, Inc. operates as a subsidiary of Emergent Health Corp.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.98M | 1.73M | 2.00M | 1.22M | 1.81M | 2.46M | 2.24M | 1.98M | 1.80M | 1.37M | 1.50M | 1.24M | 987.73K | 1.34M | 1.24M | 852.26K | 645.87K | 210.29K | 105.53K | 412.62K | 23.30M | 22.76M | 21.83M | 19.47M | 29.30M | 26.10M | 22.30M | 15.50M |
| Cost of Revenue | 1.18M | 2.01M | 942.38K | 582.85K | 1.20M | 1.28M | 1.27M | 834.01K | 609.05K | 652.44K | 567.83K | 416.42K | 342.87K | 376.51K | 402.34K | 401.02K | 209.05K | 165.23K | 177.35K | 572.32K | 14.87M | 14.26M | 13.12M | 11.24M | 16.90M | 14.80M | 12.10M | 8.60M |
| Gross Profit | 799.56K | -284.66K | 1.06M | 637.74K | 612.93K | 1.18M | 967.14K | 1.14M | 1.19M | 722.31K | 935.46K | 821.80K | 644.86K | 963.52K | 842.57K | 451.25K | 436.82K | 45.06K | -71.82K | -159.71K | 8.43M | 8.50M | 8.71M | 8.23M | 12.40M | 11.30M | 10.20M | 6.90M |
| Gross Profit Ratio | 40.43% | -16.46% | 52.94% | 52.25% | 33.86% | 47.91% | 43.17% | 57.80% | 66.12% | 52.54% | 62.23% | 66.37% | 65.29% | 71.90% | 67.68% | 52.95% | 67.63% | 21.43% | -68.06% | -38.71% | 36.19% | 37.35% | 39.88% | 42.26% | 42.32% | 43.30% | 45.74% | 44.52% |
| Research & Development | 1.37M | 969.53K | 1.10M | 1.14M | 1.16M | 1.21M | 988.60K | 1.18M | 1.11M | 952.56K | 1.04M | 965.62K | 969.47K | 1.23M | 1.18M | 1.81M | 2.02M | 1.43M | 498.58K | 419.94K | 1.82M | 2.61M | 2.30M | 2.44M | 3.30M | 2.50M | 1.30M | 0.00 |
| General & Administrative | 8.21M | 3.24M | 3.82M | 3.43M | 4.58M | 3.44M | 3.42M | 2.82M | 2.90M | 2.39M | 2.47M | 2.61M | 2.03M | 1.92M | 1.81M | 1.92M | 2.17M | 0.00 | 0.00 | 0.00 | 4.35B | 4.11B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 730.71K | 401.44K | 324.73K | 649.78K | 680.63K | 1.01M | 1.21M | 872.37K | 745.57K | 721.23K | 752.29K | 714.64K | 931.07K | 1.20M | 1.05M | 1.69M | 1.39M | 0.00 | 0.00 | 0.00 | 3.28B | 3.29B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 8.94M | 3.64M | 4.14M | 4.08M | 5.26M | 4.45M | 4.63M | 3.70M | 3.65M | 3.11M | 3.23M | 3.32M | 2.97M | 3.13M | 2.86M | 3.61M | 3.56M | 2.67M | 1.85M | 1.81M | 7.63M | 7.39M | 6.89M | 7.58M | 8.40M | 8.20M | 6.60M | 5.40M |
| Other Expenses | 0.00 | 7.85K | 0.00 | 0.00 | 4.02K | -1.31M | -192.48K | -1.11K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -10.00K | 0.00 | 0.00 | 0.00 | 1.61M | 1.60M | 1.30M | 900.00K | 600.00K |
| Operating Expenses | 10.30M | 4.61M | 5.25M | 5.22M | 6.42M | 5.65M | 5.61M | 4.88M | 4.75M | 4.06M | 4.26M | 4.29M | 3.94M | 4.36M | 4.04M | 5.42M | 5.58M | 4.10M | 2.35M | 2.22M | 9.44M | 10.01M | 9.20M | 11.63M | 13.30M | 12.00M | 8.80M | 6.00M |
| Cost & Expenses | 11.48M | 6.63M | 6.19M | 5.81M | 7.62M | 6.93M | 6.89M | 5.71M | 5.36M | 4.71M | 4.83M | 4.70M | 4.28M | 4.74M | 4.44M | 5.82M | 5.79M | 4.27M | 2.52M | 2.79M | 24.31M | 24.27M | 22.32M | 22.87M | 30.20M | 26.80M | 20.90M | 14.60M |
| Interest Income | 0.00 | 10.44M | 14.45M | 8.34M | 5.28M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.30K | 4.99K | 57.95K | 286.60K | 0.00 | 0.00 | 0.00 | 19.39M | 41.81M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 15.58M | 10.44M | 14.45M | 8.34M | 5.28M | 4.17M | 6.06M | 4.50M | 4.15M | 1.30M | 339.82K | 133.42K | 136.60K | 2.30K | 4.99K | 57.95K | 0.00 | 0.00 | 0.00 | 0.00 | 291.28K | 247.97K | 438.01K | 1.62M | 0.00 | 100.00K | 0.00 | 200.00K |
| Depreciation & Amortization | 112.45K | 233.26K | 175.32K | 203.89K | 183.40K | 94.27K | 8.58K | 17.94K | 25.29K | 65.71K | 79.56K | 107.52K | 141.32K | 197.43K | 204.34K | 200.00K | 179.45K | 146.26K | 106.55K | 146.27K | 1.25M | 1.30M | 1.42M | 1.61M | 1.60M | 1.30M | 900.00K | 600.00K |
| EBITDA | -9.39M | -5.40M | -5.53M | -7.46M | -6.41M | -5.44M | -4.65M | -3.72M | -3.24M | -3.24M | -3.67M | -3.36M | -2.72M | -2.95M | -2.99M | -4.71M | -5.15M | -3.91M | -2.42M | -2.25M | -1.19M | -201.80K | 924.66K | -1.79M | -111.76K | 344.11K | 2.30M | 1.50M |
| EBITDA Ratio | -474.82% | -275.86% | -203.51% | -365.27% | -313.70% | -231.80% | -215.62% | -188.15% | -196.91% | -238.05% | -188.27% | -282.74% | -318.79% | -257.14% | -240.36% | -559.26% | -1,083.26% | -2,106.53% | -5,368.43% | -434.63% | 1.00% | -0.89% | 4.24% | -1.70% | 2.39% | 18.39% | 8.97% | 9.68% |
| Operating Income | -9.50M | -4.90M | -4.19M | -4.59M | -5.81M | -4.48M | -4.65M | -3.74M | -3.57M | -3.34M | -3.33M | -3.46M | -3.29M | -3.40M | -3.20M | -4.97M | -5.15M | -4.06M | -2.42M | -2.38M | -1.01M | -1.50M | -490.59K | -3.40M | -900.00K | -700.00K | 1.40M | 900.00K |
| Operating Income Ratio | -480.51% | -283.25% | -209.01% | -375.70% | -320.75% | -182.15% | -207.41% | -189.00% | -198.32% | -242.83% | -221.33% | -279.73% | -333.10% | -253.63% | -256.77% | -582.73% | -796.94% | -1,929.78% | -2,292.44% | -577.35% | -4.35% | -6.61% | -2.25% | -17.48% | -3.07% | -2.68% | 6.28% | 5.81% |
| Total Other Income/Expenses | -19.81M | -11.18M | -15.97M | -11.42M | -6.07M | -5.22M | -6.07M | 1.03M | -3.85M | -1.27M | -757.24K | 11.42K | 293.83K | 246.78K | 4.99K | 57.95K | 2.32M | 899.65K | 3.62M | -301.04K | -2.37M | -206.16K | -380.49K | -3.06M | -413.83K | -4.30M | 300.00K | -100.00K |
| Income Before Tax | -29.31M | -16.08M | -20.15M | -16.01M | -11.88M | -9.70M | -10.72M | -2.71M | -7.42M | -4.61M | -4.08M | -3.45M | -3.00M | -3.15M | -3.19M | -4.91M | -2.83M | -3.16M | 1.20M | -2.68M | -1.29M | -1.71M | -871.08K | -6.46M | -1.30M | -5.00M | 1.70M | 800.00K |
| Income Before Tax Ratio | -1,482.19% | -929.64% | -1,006.48% | -1,311.29% | -656.25% | -394.62% | -478.27% | -136.96% | -412.49% | -335.52% | -271.70% | -278.81% | -303.35% | -235.22% | -256.37% | -575.93% | -438.45% | -1,501.96% | 1,139.95% | -650.31% | -5.52% | -7.51% | -3.99% | -33.19% | -4.44% | -19.16% | 7.62% | 5.16% |
| Income Tax Expense | 0.00 | 747.67K | 14.45M | 8.34M | -217.17K | -1.05M | 5.86M | 4.50M | 4.15M | 1.30M | 757.24K | -2.01K | 136.60K | -23.71K | -623.26K | 0.00 | -520.21K | -745.35K | 329.97K | -941.35K | 3.43K | 2.94K | 15.68K | 1.15M | -500.00K | -600.00K | 700.00K | 300.00K |
| Net Income | -29.31M | -16.82M | -34.60M | -24.35M | -11.66M | -9.70M | -10.72M | -2.71M | -7.42M | -4.61M | -4.08M | -3.45M | -3.00M | -3.13M | -2.57M | -4.91M | -1.16M | -2.41M | 872.97K | 12.71M | -1.29M | -1.49M | 3.45M | -8.00M | -800.00K | -4.40M | 1.00M | 500.00K |
| Net Income Ratio | -1,482.19% | -972.88% | -1,728.14% | -1,994.92% | -644.25% | -394.62% | -478.27% | -136.96% | -412.49% | -335.52% | -271.70% | -278.64% | -303.35% | -233.45% | -206.31% | -575.93% | -178.93% | -1,147.52% | 827.26% | 3,080.97% | -5.53% | -6.54% | 15.80% | -41.09% | -2.73% | -16.86% | 4.48% | 3.23% |
| EPS | -1.51 | -1.52 | -5.21 | -7.37 | -5.87 | -6.34 | -9.62 | -2.97 | -10.73 | -9.70 | -10.37 | -10.19 | -13.58 | -34.93 | -33.29 | -67.11 | -16.68 | -30.21 | 18.60 | 55.80 | -5.68 | -6.70 | 16.80 | -43.80 | -5.14 | -28.36 | 6.90 | 5.10 |
| EPS Diluted | -1.51 | -1.52 | -5.21 | -7.37 | -5.87 | -6.34 | -9.62 | -2.97 | -10.73 | -9.70 | -10.37 | -10.19 | -13.58 | -34.93 | -33.29 | -67.11 | -16.68 | -30.21 | 17.70 | 55.80 | -5.68 | -6.70 | 16.80 | -43.80 | -5.14 | -28.36 | 6.30 | 4.20 |
| Weighted Avg Shares Out | 23.34M | 11.06M | 6.64M | 3.30M | 1.99M | 1.53M | 1.11M | 911.31K | 690.87K | 475.49K | 394.06K | 338.47K | 220.61K | 89.57K | 77.14K | 73.14K | 69.29K | 79.87K | 99.09K | 228.34K | 227.02K | 222.02K | 206.81K | 182.67K | 155.66K | 155.17K | 144.93K | 145.93K |
| Weighted Avg Shares Out (Dil) | 23.34M | 11.06M | 6.64M | 3.30M | 1.99M | 1.53M | 1.11M | 911.31K | 690.87K | 475.49K | 394.06K | 338.47K | 220.61K | 89.57K | 77.14K | 73.14K | 69.29K | 79.87K | 103.60K | 228.34K | 227.02K | 222.02K | 208.13K | 182.67K | 155.66K | 155.17K | 158.73K | 145.93K |
Pressure BioSciences Reports New Client Launching Around UltraShear Nanoemulsions Platform with $300,000-plus Product Order
SOUTH EASTON, Mass., Jan. 18, 2024 (GLOBE NEWSWIRE) -- Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBIO” or the “Company”), a pioneer in the development and distribution of broadly enabling pressure-based instruments, consumables, and specialty process development and testing services across global...
Pressure BioSciences' New Consumer Products Unit Continues Long Sales Relationship with Dominant U.S. Retailer, Launching 2024 with Quarter Million Dollar Shipment in January
Uncle Bud's, PBIO's New Consumer Products Business Unit, Kicks Off 2024 with a $252,000 Shipment of Sunburn Soother to One of the World's Largest Retailers Uncle Bud's, PBIO's New Consumer Products Business Unit, Kicks Off 2024 with a $252,000 Shipment of Sunburn...
Pressure BioSciences Signs Definitive Agreement to Acquire Uncle Bud's, Forward Integrating PBIO's UltraShear Platform into Multiple Markets
SOUTH EASTON, Mass.--(BUSINESS WIRE)--Pressure BioSciences (OTCQB: PBIO) Strategically Acquires Leading Health & Wellness Firm Uncle Bud's Hemp and CBD.
Pressure BioSciences Signs Definitive Agreement to Acquire Uncle Bud's, Forward Integrating PBIO's UltraShear Platform into Multiple Markets
SOUTH EASTON, Mass.--(BUSINESS WIRE)--Pressure BioSciences (OTCQB: PBIO) Strategically Acquires Leading Health & Wellness Firm Uncle Bud's Hemp and CBD.
Pressure BioSciences' BaroFold Platform Expected to Revolutionize Biopharmaceutical Production with Help from New Computational (AI/ML) Technologies
Artificial Intelligence/Machine Learning Also Expected to Significantly Accelerate Advancements in PBIO's Patented, Innovative, and Enabling UltraShear Processing Platform SOUTH EASTON, MA / ACCESSWIRE / January 4, 2024 / Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBIO" or the "Company"), a leading developer and...
Pressure BioSciences' Celebrates Second Groundbreaking Article Published This Month on its Transformative, Patented UltraShear Technology Processing Platform
Beyond Formidable Enhancements for the Food and Beverage Industry, UST Offers Promising Applications in Drug Delivery, Cosmetics, Biotechnology, Agriculture, and Advanced Nanomaterials SOUTH EASTON, MA / ACCESSWIRE / December 21, 2023 / Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBIO" or the "Company"),...
Pressure BioSciences' UltraShear Platform Maintains Nutritional, Sensory, and Other Important Qualities of Liquid Foods While Inactivating Foodborne Bacterial Spores
Novel Results Published in Respected Peer-Reviewed Food Science and Emerging Technologies Journal - Discussions Underway with Beverage Industry Companies SOUTH EASTON, MA / ACCESSWIRE / December 12, 2023 / Pressure BioSciences, Inc. (OTCQB:PBIO), a leading developer and provider of broadly...
Pressure BioSciences and Veterans Service Team Launch UltraShear Best-in-Class Nano-CBD Topical Spray - MMA Champ Cat Zingano Now Official VST Ambassador
Initial Revenue Expected to Reach $1.0 Million in Year 1 Increasing to More Than $10 Million in Year 5 of the Agreement. "Valor CBD" Topical Spray Now Available on the VST Website.
Pressure BioSciences, Inc. Reports Q3 2023 Financial Results, Provides Business Update, and Offers Guidance for Remainder of 2023
Investor Call Scheduled for Tuesday, November 21, 2023 at 4:30 p.m. ET SOUTH EASTON, MA / ACCESSWIRE / November 21, 2023 / Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling,...
Pressure BioSciences, Inc. to Discuss Third Quarter 2023 Financial Results and Provide Business Update
Conference Call Scheduled for Tuesday, November 21 at 4:30pm ET SOUTH EASTON, MA / ACCESSWIRE / November 20, 2023 / Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBIO" and the "Company") today announced that the Company will host a teleconference to discuss its...
Source: https://incomestatements.info
Category: Stock Reports